BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1
Terminated
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT05244070
- Locations
- 🇺🇸
Local Institution - 0026, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0007, Boston, Massachusetts, United States
🇺🇸Local Institution - 0005, Birmingham, Alabama, United States
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT05236738
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
Recruiting
- Conditions
- Non-Valvular Atrial Fibrillation (NVAF)
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 720
- Registration Number
- NCT05232643
- Locations
- 🇮🇹
Local Institution - 0001, Milano, MI, Italy
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT05217082
- Locations
- 🇺🇸
Local Institution - 0001, Morrisville, North Carolina, United States
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Completed
- Conditions
- Leukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesLeukemia, Myeloid, Acute
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 290
- Registration Number
- NCT05218902
- Locations
- 🇨🇳
Local Institution - 0001, Tianjin, Tianjin, China
Expanded Access for Anti-IL8
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05210894
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05209295
- Locations
- 🇦🇷
Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
🇨🇴Instituto Nacional De Cancerologia, Bogota, Cundinamarca, Colombia
🇺🇸University of Iowa, Iowa City, Iowa, United States
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Phase 2
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 19
- Registration Number
- NCT05197426
- Locations
- 🇺🇸
Local Institution - 0011, Huntsville, Alabama, United States
🇯🇵Local Institution - 0017, Nagoya, Aichi, Japan
🇯🇵Local Institution - 0023, Nagoya, Aichi, Japan
Expanded Access for Apixaban
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05187286
- Locations
- 🇺🇸
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170685
© Copyright 2025. All Rights Reserved by MedPath